With an estimated two billion people affected worldwide, fatty liver disease is a silent epidemic that often goes unnoticed until it’s too late. Learn the crucial early warning signs that could help ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...

There's nothing quite like a thrilling "overnight success" story. But when it comes to soul superstar Otis Redding, his meteoric rise to the top ended almost as quickly as it started.

Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare ...

A study found wastewater treatment plants are exposing Americans to "forever chemicals." PFAS can cause a range of health ...

Investors in Bilibili Inc (Symbol: BILI) saw new options become available today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BILI ...

According to data from Benzinga Pro, BILI has a 52-week high of $31.77 and a 52-week low of $8.80.

SXSW EDU®  is excited to unveil the list of finalists for its 2025 Launch Startup Competition and Student Impact Challenge. This year's selected cohorts represent teams from the United States, Brazil, ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

Bilirubin-induced neurologic dysfunction can occur in term and late-preterm healthy babies, however, can be effectively prevented through rapid reduction of the increased bilirubin load by ...

Conjugation of bilirubin and delivery to the intestine doesn't necessarily lead to excretion of the substance. Neonatal intestines contain beta-glucuronidase, an enzyme capable of reducing ...

In any case, new support levels are usually revised to the database at the beginning of the next trading session. Short BILI slightly under 18.07, target n/a, stop loss @ 18.12 Details The technical ...